Azienda Sanitaria Locale Viterbo — Clinical Trial Site

17 Registered trials

8 Currently recruiting

Organisation

Azienda Sanitaria Locale Viterbo

Location

Viterbo, Italy

Identifier

ORG-100030908

Address

Strada Sammartinese Snc, 01100, Italy

Departments

DIPARTIMENTO ONCO-EMATOLOGICO - UOC EMATOLOGIA
Dipartimento Onco-Ematologico -UOC EMATOLOGIA
Ematologia
Medical oncology
Oncologia
Oncologia e rete oncologica
Oncologia Medica
Oncology
OU Nephrology and Dialysis
Presidio Ospedaliero di Belcolle - U.O. Oncologia
U.O. Oncologia
U.O.C Oncologia
U.O.C. Oncologia e Rete Oncologica
UO Nefrologia e Dialisi
UOC Nefrologia e Dialisi
UOC Oncologia

Clinical trials at this site (17)

Search interface

A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY… Pending

2024-517861-18-00 Idiopathic IgA nephropathy (IgAN) 5
A phase III study comparing the concurrent versus the sequential administration of chemotherapy and aromatase inhibitors, as adjuvant treatm… Pending

2024-519087-41-00 Breast cancer is the most common form of cancer among w 5
Combined Dose-Finding and CV Outcomes Study with CSL300 (Clazakizumab) in Adult Subjects with ESKD Undergoing Dialysis (POSIBIL6ESKD). Recruiting

2022-500273-14-00 Atherosclerotic cardiovascular disease in patients with 10 2023-07-17
Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to Myelodysplastic Syndromes with del5q refractory/resistant/intolerant … Recruiting

2024-519310-31-00 Anemia due to MDS with del5q with IPSS-R very low, low, 4 2025-01-27
Phase III study in mCRC patients with RAS/BRAF wild type tissue and RAS/BRAF mutated in LIquid BIopsy to compare in first-line therapy FOLFI… Recruiting

2024-517863-22-00 Study population consists in patients with a diagnosis 5 2024-12-01
PHASE III RANDOMIZED STUDY OF FOLFOXIRI PLUS BEVACIZUMAB AND ATEZOLIZUMAB VERSUS FOLFOXIRI PLUS BEVACIZUMAB AS FIRST-LINE TREATMENT OF UNRES… Recruiting

2023-506632-32-00 Metastatic colorectal cancer 5 2024-10-28
Phase II study of axitinib intensification plus standard of care (SOC) compared to SOC alone after induction with nivolumab plus ipilimumab … Recruiting

2024-511397-70-00 metastatic renal cell carcinoma (mRCC) 4 2024-05-06
The study is aimed at evaluating the feasibility of a hypomethylating treatment combined with hematopoietic stem cell transplantation in com… Recruiting

2023-510515-19-00 Higher-risk-myelodysplastic syndromes 5 2020-11-27
RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone orenzalutamide) as first-line… Recruiting

2024-518623-30-00 metastatic castration resistant prostate cancer without 6 2020-10-01
Study to identify the most appropriate therapy for patients with Acute Myeloid Leukemia carrying FLT3 mutation, using the PBC biomarker to c… Recruiting

2023-505901-17-00 Acute Myeloid Leukemia (LMA) with FLT3 mutation 5 2020-04-24
Efficacy of PErioperative PEmbrolizumab treatment in patients with resectable metastases from kidney cancer. The PE-PE study Ended

2024-512180-31-00 Oligometastatic renal cell carcinoma 4 2025-03-14
Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer Ended

2023-506771-10-00 Breast Neoplasm, Neoplasm Metastasis 5 2022-03-11
Study aimed at evaluating the efficacy of a combination treatment (decitabine and venetoclax) in patients with Acute Myeliode Leukemia who a… Ended

2023-510241-16-00 Acute Myeloid Leukemia secondary to myeloproliferative 4 2021-12-03
Comparison of two strategies that use the same drugs but with inverted sequence for the treatment of patients with metastatic colorectal can… Ended

2024-513296-41-00 Colorectal cancer spread at distance, RAS BRAF wild typ 4 2020-12-03
Olaparib as adjuvant treatment in patients with germline BRCA mutated high risk HER2negative primary breast cancer. Ended

2024-511096-15-00 Breast Cancer 5 2014-08-01
Use of circulating tumor dna test to intensify post-operative treatment of patients with resected colon cancer. Halted

2024-515152-20-00 Stage III and high-risk stage II resected colon cancer 4 2023-03-02
VISIONARY Trial: Phase 3 Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN) Ended

2022-500079-30-00 IgA Nephropathy 5 2022-11-03